NCT03945604: A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Therapeutic Antibody, Immunotherapy, Tyrosine-Kinase Inhibitor, Misc Inhibitor

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 80 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have at least -line of chemotherapy fail at stage of metastasis
Exclusions: Patients with untreated central nervous system metastasis; Patients with prior anti-PD-1/PD-L1 therapy and//or PARP inhibitors

Comments are closed.

Up ↑